A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2308-2315

  Siegel, David ^a   Jagannath, Sundar ^a   Vesole, David H ^a   Borello, Ivan ^b   Mazumder, Amitabha ^a   Mitsiades, Constantine ^c   Goddard, Jill ^d   Dunbar, Joi ^d   Normant, Emmanuel ^d   Adams, Julian ^d   Grayzel, David ^d   Anderson, Kenneth C ^c   Richardson, Paul ^c  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Infinity Pharmaceuticals Inc   (United States)

Author keywords

HSP90; IPI 504; Multiple myeloma; Phase 1; Relapsed refractory

Indexed keywords

17 AMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; LENALIDOMIDE; RETASPIMYCIN; TANESPIMYCIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEADACHE; HUMAN; INJECTION SITE PAIN; MALE; MAXIMUM TOLERATED DOSE; METABOLITE; MULTIPLE MYELOMA; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SINUS BRADYCARDIA; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT RESPONSE; URINE COLOR;

AGED; ANTINEOPLASTIC AGENTS; BENZOQUINONES; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; TREATMENT OUTCOME;

EID: 82255196140     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.600481     Document Type: Article

References (29)

1. Barlogie B, Shaughnessy J, Epstein J, et al. Plasma cell myeloma. In: Lichtman M, Beutler E, Kipps T, et al., editors. Williams hematology. 7th ed online. New York: McGraw-Hill; 2006. pp. 1279-1304.
2. Linker CA. Blood disorders. In: McPhee SJ, Papadakis MA, Tierney LM, editors. Current medical diagnosis & treatment. 47th ed. New York: McGraw-Hill; 2008. p. 422-472.
3. Jemal A, Siegel R, Ward E, et al. Cancer Statistics. CA Cancer J Clin 2009;59:225-249.
4. Kumar K, Blade J, Crowley J, et al. Outcome of patients with myeloma relapsing after IMID and bortezomib therapy: a multicenter study from the International Myeloma Foundation Working Group. Haematologica 2010;95(Suppl. 2): Abstract 0376.
5. Goetz MP, Toft DO, Ames MM, et al. Te HSP90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-1176. (Pubitemid 37039035)
6. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-772. (Pubitemid 41400776)
7. Workman P, Burrows F, Neckers L, et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007;1113:202-216. (Pubitemid 350015011)
8. Fumo G, Akin C, Metcalfe DD, et al. 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004;103:1078-1084. (Pubitemid 38129574)
9. Shimamura T, Lowell AM, Engelman JA, et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005;65:6401-6408. (Pubitemid 40994428)
10. Ge J, Normant E, Porter JR, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of HSP90. J Med Chem 2006;49:4606-4615. (Pubitemid 44162687)
11. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999;13:1211-1233. (Pubitemid 29250189)
12. Lee AH, Iwakoshi NN, Anderson KC, et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003;100:9946-9951. (Pubitemid 37087048)
13. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-4916. (Pubitemid 43882644)
14. Patterson J, Palombella VJ, Fritz C, et al. IPI-504, a novel and soluble HSP90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 2008;61:923-932. (Pubitemid 351423119)
15. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-383. (Pubitemid 37128324)
16. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against HSP90. Proc Natl Acad Sci USA 2006;103:17408-17413. (Pubitemid 44788982)
17. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcomittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123. (Pubitemid 28435189)
18. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-2617. (Pubitemid 36741588)
19. Kim HR, Kang HS, Kim HD. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 1999;48:429-433.
20. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-1087. (Pubitemid 46202262)
21. Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-315.
22. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-3391. (Pubitemid 40627891)
23. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-6093. (Pubitemid 44703773)
24. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-1893. (Pubitemid 46211366)
25. Wagner AJ, Morgan JA, Chugh R, et al. Inhibition of heat shock protein (HSP90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. J Clin Oncol 2008;26(15 Suppl.): Abstract 10503.
26. Banerji U, Walton M, Raynaud F, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11:7023-7032. (Pubitemid 41428762)
27. Porter JR, Ge J, Lee J, et al. Ansamycin inhibitors of HSP90; nature's protoytpe for anti-chaperone therapy. Curr Top Med Chem 2009;9:1386-1418.
28. Richardson PG, Chanan-Khan A, Lonial S, et al. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: f nal results of a phase I/II study. J Clin Oncol 2009;27(15 Suppl.): Abstract 8503.
29. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-1100. (Pubitemid 43156310)